Patents by Inventor Spencer Wei

Spencer Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220053740
    Abstract: Provided herein are mice that are heterozygous knock outs for Ctla4 and homozygous knockouts for Pdcd1 (Ctla4+/? Pdcd1?/? mice), which may suffer from autoimmunity, including myocarditis and insulin-dependent diabetes mellitus. Also provided are methods of using such mice to screen for therapeutic agents that mitigate immune-related adverse events.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 24, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Spencer WEI, James ALLISON
  • Publication number: 20220010337
    Abstract: Methods and compositions related to intracellular delivery of gene editing proteins are provided. The invention relates to compositions and methods for transporting gene editing polypeptides, such as Cas9 or Cas12, into a cell ex vivo or in vivo. The invention includes a targeted active gene editing (TAGE) agent that includes an extracellular cell membrane binding moiety, e.g., an antigen binding polypeptide, a cell penetrating peptide (CPP), a ligand, or combinations thereof, that specifically binds to an extracellular cell membrane-bound molecule (e.g., a cell surface molecule), and a site-directed modifying polypeptide that recognizes a nucleic acid sequence. The extracellular cell membrane binding moiety (e.g.
    Type: Application
    Filed: September 21, 2021
    Publication date: January 13, 2022
    Applicant: Spotlight Therapeutics
    Inventors: Hariharan Jayaram, Rina Mepani, Christopher Richardson, Steven Strutt, Eric Estrin, Jillian Astarita, Spencer Wei, Roberto Maldonado